A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06548230
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06545682
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT06545604
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Randomized Controlled Trial to Assess the Impact of Live and Recorded Music-Based Interventions on Pre-operative Stress, Mood, Pain and Biomarkers, in Neurosurgical Patients (Music-STAR Trial)
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 132
- Registration Number
- NCT06536504
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Opiophobia in Postsurgical Adults With Cancer
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06536283
- Locations
- 🇺🇸
The Univerisity of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Impact of Perioperative Anesthetic Management on Renal Cancer Progression.
Withdrawn
- Conditions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT06536244
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
AIM4 AI and Mechanistic Modeling in Molecular Medicine
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT06535828
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT06522373
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06522386
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 168
- Registration Number
- NCT06522360
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath